£540
−94%vs Jan 2024ActiveSC586605Private limited companyInsch
CALLIDUS BIOMOLECULES LIMITED
Significant control: Daniel Matthew Ozanne (75–100%)
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Callidus Biomolecules Limited: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
Coming soon · product and service lists
What does Callidus Biomolecules Limited sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01
Summary
CALLIDUS BIOMOLECULES LIMITED is an active private limited company (company number SC586605) incorporated on 24 January 2018, registered in Insch. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest micro accounts cover the period ending 31 January 2025, showing net assets of £540, with 1 employee on average. As micro-entity accounts, no profit and loss account is filed, so turnover and profit are not public. Net assets fell 94% on the prior period (£9,127).
Peer position · net assets
By net assets it sits in the lower half of 2,418 comparable companies in the UK (median £1,000, upper quartile £92k).
02
Ownership and control
- Dr Daniel Matthew Ozanne
- owns 75–100% of shares
- holds 75–100% of voting rights
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
03
Key dates
- Incorporated
- 24 January 20188 yrs ago
- Next accounts due
- 31 October 2026in 5 days
- Confirmation statement due
- 7 February 2027in 104 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
04
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Micro Entity
- Size band
- MicroCompanies Act thresholds
05
Financials
Not reported
Not disclosed
1
No changevs Jan 2024| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 January 2025 | £540 | — | — | £4,729 | — | — | 1 |
| 31 January 2024 | £9,127 | — | — | £5,900 | — | — | 1 |
Current ratio0.6Current assets ÷ creditors within one year
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing; micro-entity accounts contain no profit and loss account.
06
Filing and accounts signals
- Net assets above zeroNet assets £540 at 31 January 2025
- Net assets down 25% or more on the prior period-94.1% vs prior period
- Current assets below creditors within one yearCurrent ratio 0.6
- Incorporated five or more years agoIncorporated 24 January 2018
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
07
Timeline
- Confirmation statement duein 104 days
- Next accounts duein 5 days
- Accounts period endNet assets £540 · micro accounts
- Accounts period endNet assets £9,127 · micro accounts
- Incorporated
08
Similar companies in Aberdeen
- PELLA HOUSE LTDPeterculter · inc. May 2018
- MYCONOURISH LIMITEDAberdeen · inc. Sept 2018
- RAB MICROFLUIDICS RESEARCH AND DEVELOPMENT COMPANY LIMITEDAberdeen · inc. Aug 2016
- NODTHERA LIMITEDAberdeen · inc. Jul 2016
- TAURX THERAPEUTICS MANAGEMENT LTD.Aberdeen · inc. Mar 2016
- TAURX THERAPEUTICS EUROPE LTD.Aberdeen · inc. Mar 2016
All companies incorporated on 24 January 2018 · in Jan 2018.
09
Reminders for CALLIDUS BIOMOLECULES LIMITED
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.